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Breast cancer survivors often experience psychological distress shortly after diagnosis. Long-
term psychological effects, however, have not been clearly demonstrated.  
Methods 
This cross-sectional cohort study included 350 breast cancer survivors and 350 age and general 
practitioner matched women. The median follow-up was 10 years. We compared with logistic 
regression, breast cancer survivors to controls on having (severe) symptoms of depression 
and/or anxiety, as measured with the Hospital Anxiety and Depression Scale. In multivariable 
logistic regression, we adjusted the results for a history of depression or prescription of 
antidepressants. 
Results 
Breast cancer survivors experienced more often symptoms of depression (10.6%) compared to 
controls (4.9%) and symptoms of anxiety (18.6%) compared to controls (16.3%). The odds of 
symptoms of depression (OR 2.3, 95%CI 1.3-4.2), severe symptoms of depression (OR 3.3, 
95%CI 1.1-10.3) and severe symptoms of anxiety (OR 2.1, 95%CI, 1.1-4.0) were significantly 
higher for breast cancer survivors in comparison to the controls, even after adjusting for history 
of depression or prescription of antidepressants. No significant difference was seen for mild 
symptoms of anxiety. 
Conclusions 
Breast cancer survivors have an increased odds of experiencing (severe) symptoms of 
depression and severe symptoms of anxiety compared to controls, for up to at least 10 years 
after diagnosis. 
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Highlights 
 In our study, a large proportion of BC survivors did not experience symptoms of 
depression or anxiety. 
 Long-term BC survivors are at increased odds of (severe) symptoms of depression 
 Long-term BC survivors are at increased odds of severe symptoms of anxiety 
 The increased odds are independent of a history of depression or antidepressants 
 The increased odds are independent of time since BC diagnosis 
 These increased odds seem to persist at least 10 years after BC diagnosis 
 
1. INTRODUCTION 
Breast cancer is the most common cancer in women1, 2. Fortunately, the survival of breast cancer 
has improved due to better screening and better treatments3. Numbers from the Netherlands 
show a 5-year survival rate of up to 88%4. Hence, the number of breast cancer survivors is also 
increasing.  
The diagnosis of cancer and its treatment can have a great impact on a patient’s psychological 
well-being5-8. However, both the clinicians and the patients may not be aware of possible long-
term psychological impact and patients may not receive the proper support. No long-term follow 
up data are available with respect to the occurrence of psychological distress in breast cancer 
patients9. Therefore, it is important to know how prevalent long-term psychological distress is 
among breast cancer survivors. For women with breast cancer, this impact is mainly studied in 
the first five years after diagnosis when they still have follow-up controls with their 
oncologists10. In this period, Burgess et al. found a prevalence of 48% for depression, anxiety, or 
both for breast cancer survivors.11 Which, they said, is twice as high as in the general female 
population. A recent systematic review of studies (2015) on symptoms of depression and 
anxiety among breast cancer survivors showed a widely distributed prevalence of 9.4-66.1% 
and 17.9-33.3%, respectively10. A few of the studies included women beyond the five years after 
diagnosis, and only two focused solely on women five years or more after their diagnosis of 
breast cancer12, 13. One of these two found that 13% of women experienced severe symptoms of 
depression12. However, they did not have a control population to evaluate if this proportion is 
more than on average. The other study evaluated women 5, 10 or 15 years after breast cancer 
diagnosis on quality of life and found that they had a higher score on symptoms of anxiety than 
random control women13. Unfortunately, the patient group and the control group significantly 
differed on age, environment (urban/rural) and income, which might have had an influence on 
the comparability on psychological well-being. Studies after 2015 have only been performed 
within the first years of diagnosis or in a hospital setting14, 15.  
For clinicians, survivors, and future guidelines, it is important to know if psychological distress 
is more prevalent among long-term breast cancer survivors than among women without cancer, 
in order to provide sufficient long-term support. Therefore in this study, we assessed symptoms 
of depression and anxiety at least five years after the diagnosis of breast cancer and compared 
with the results of women without a history of cancer, who were of the same age and general 
practitioner (GP).  
2. METHODS 
2.1 Context 
In the Netherlands, all citizens are registered with a GP in their own residential area16. These GPs 
use electronic patient registers with coding systems of diagnosis (International Classification for 
Primary Care, ICPC) and medication prescriptions  (Anatomical Therapeutic Chemical 
classification system, ATC)17, 18. GPs are gatekeepers to secondary healthcare, which means that 
patients have to be referred by their GPs to medical specialists.  
2.2 BLOC study design  
Data for this study was derived from the Breast cancer Long-term Outcome of Cardiac 
dysfunction (BLOC)-study19. The primary outcome of the BLOC-study was the prevalence of 
long-term systolic and diastolic cardiac dysfunction among breast cancer survivors in 
comparison to matched controls. This cross-sectional cohort included 350 breast cancer 
survivors treated with chemo- and/or radiotherapy at least five years ago, and 350 randomly 
selected women from the same age and GP from the Northern part of the Netherlands 
(Supplementary Figure 1), recruited from 80 GPs. The control was randomly selected from the 
same GP database, from all women of the same age (+/- 1 year) as the breast cancer survivor. 
Exclusion criteria for the control were a history of cancer or cancer treatment. In both groups, 
women were excluded if they were not able to come to the university hospital according to their 
GP due to severe mental or physical illness.  At the time of the cross-sectional assessment, the GP 
files of both breast cancer survivors and controls were searched for the code P76 and the date of 
the first diagnosis of depression was extracted. Furthermore, the first prescriptions of 
antidepressants (ATC-code N06A), anxiolytics (ATC-code N05B), and hypnotics and sedatives 
(ATC-code N05C) were analysed. Since the antidepressant amitriptyline can also be prescribed 
as an analgesic, it was excluded when prescribed for pain. The date of diagnosis of women with 
breast cancer functioned as the index date for the matched women. Therefore, the time since 
diagnosis for the control group is the time since the index date. The median age at the time of 
breast cancer diagnosis was 51 years (inter-quartile range [IQR] 45-57). The median follow-up 
was 10 years (IQR 7-14) years. The study is registered at clinicaltrials.gov [ID:NCT01904331]. 
The medical ethics committee of the University Medical Center Groningen (UMCG) approved this 
study, and all participants gave written informed consent. The study was performed in 
accordance with the Declaration of Helsinki. 
2.3 Current study end-points  
The primary outcome was the prevalence of (severe) symptoms of depression and/or anxiety as 
measured by the Hospital Anxiety and Depression Scale (HADS)20. This questionnaire measures 
symptoms of both depression (HADS-D) and anxiety (HADS-A). It is a self-reported scale with 14 
items scoring each 0-3, with a maximum score of 21 for either symptoms of depression or 
anxiety. Cut-off values are ≥ 8 for mild symptoms of depression/anxiety and ≥ 11 for severe 
symptoms of depression/anxiety. The HADS has been validated for both the general population 
and the breast cancer population21, 22. The secondary outcomes were the prevalence of a 
diagnosis of depression as registered by GPs after the diagnosis of breast cancer and/or a 
prescription of antidepressants after breast cancer diagnosis. 
2.4 Statistical analyses 
In the analysis, a diagnosis of depression and/or prescription of an antidepressant could be a 
determinant as well as an outcome. Survivors and controls with the first diagnosis of depression 
and/or first prescription of an antidepressant before the date of breast cancer diagnosis were 
considered as having a ‘history of depression’. It is important to adjust for a history of 
depression, since depression is often a recurrent diagnosis. Survivors and controls with the first 
diagnosis of depression and/or first prescription of an antidepressant after the date of breast 
cancer diagnosis were considered as having an ‘outcome of depression’. The diagnosis of 
depression and prescription of antidepressants were combined since some GPs may have the 
tendency to prescribe antidepressants for depression without coding a diagnosis of depression. 
Table 1 describes participants’ characteristics at the time of breast cancer diagnosis, including 
the number of survivors with a history of depression and the use of psychotropic medication 
before the date of breast cancer diagnosis. In table 2, the outcomes are described. For future 
comparability with other studies, both the continued and dichotomous values of the HADS are 
reported and tested with the Mann-Whitney U test. 
In univariate logistic regression analyses, breast cancer survivors were compared to controls on 
the odds of having (severe) symptoms of depression and (severe) symptoms of anxiety as scored 
with the HADS, and on having diagnosis of depression and/or first prescription of an 
antidepressant after the date of breast cancer diagnosis (Table 2). In this way, odds ratios (ORs) 
and 95% confidence intervals (95% CIs) were estimated. To adjust for having a history of 
depression, multivariable logistic regression analyses were performed by adding this variable 
(Table 3 and 4). Data is presented stratified for depression and anxiety. In univariate logistic 
regression analyses the time since diagnosis for breast cancer survivors with increased HADS-
scores were compared to the time since diagnosis for other breast cancer survivors. 
To visualize the effect of time since follow-up, a graphical overview of the course of symptoms of 
depression and anxiety over time was constructed. The percentage of breast cancer survivors 
with an increased score on the HADS was compared to the percentage of controls, grouped by 
time since diagnosis, per two years. The minimum of women per time-subgroup had to be 20. All 
analyses were performed with the use of IBM SPSS statistics 23.
3. RESULTS 
No significant differences were found between breast cancer survivors or controls regarding 
patient and therapy characteristics (Table 1)19. Only a prescription of hypnotics/sedatives 
before breast cancer diagnosis was significantly higher among controls compared to breast 
cancer survivors, respectively 9.4% and 3.7%.  
All woman completed the HADS questionnaire at the time of inclusion (median 10 years after 
breast cancer diagnosis). At this time 3.7% of breast cancer survivors experienced severe 
symptoms of depression compared to 1.1% of controls; a significant difference OR 3.3 (95%CI, 
1.1-10.3). Concerning severe symptoms of anxiety, there was a significant difference between 
breast cancer survivors (8%) compared to controls (4%; OR 2.1 [95%CI, 1.1-4.0]), (Table 2). 
The proportion of women with mild symptoms of depression was significantly higher for breast 
cancer survivors compared to controls (10.6% versus 4.9%; OR 2.3 [95%CI, 1.3-4.2]). For mild 
symptoms of anxiety, the difference was not significant 18.6% versus 16.3%; OR 1.2 [95%CI, 0.8-
1.7]). 
The answer to the HADS-D question ‘I feel as if I am slowed down’ showed the largest difference; 
20.3% of BC survivors responded very often/almost-all-the time compared to 9.5% of the 
controls. 
No significant differences were seen between breast cancer survivors and controls when 
comparing the continuous score on the HADS-D or HADS-A, p-values 0.197 and 0.056, 
respectively. After the diagnosis of breast cancer, no differences were seen in the registration of 
GPs concerning the diagnoses of depression or prescription of medication. 
3.1 Multivariable analysis 
After adjusting history of depression as registered by the GPs before the date of breast cancer, all 
odds were significantly higher for breast cancer survivors compared to controls: severe 
symptoms of depression (HADS-D≥ 11; OR 3.3 [95%CI 1.1-10.3]), severe symptoms of anxiety 
(HADS-A≥ 11; OR 2.1 [95%CI 1.1-4.1]), mild symptoms of depression (HADS-D≥ 8; OR 2.3 
[95%CI 1.3-4.2]) and mild symptoms of anxiety (OR 2.1 [95%CI 1.1-3.2]). This is shown in table 
3. 
3.2 Time since diagnosis 
Time since diagnosis was not associated with symptoms of (severe) depression or anxiety 
among breast cancer survivors. The figures visualize the proportion of women (breast cancer 
survivors and controls) with (severe) symptoms of depression (Figure 1) or anxiety (Figure 2) 
with a specific follow-up duration. The proportion of women with severe or mild symptoms of 
depression and severe symptoms of anxiety is higher among the breast cancer survivors than 




To our knowledge, no other study included women at least five years after breast cancer 
diagnosis from the general population and compared their symptoms of depression and anxiety 
with women of the same age without any cancer. When discussing the findings, it is important to 
realize that a large proportion of the long-term breast cancer survivors in our study did not 
experience symptoms of depression or anxiety (89.4% and 81.4%, respectively) at the moment 
of measurement. This does not exclude the possibility that they have experienced symptoms of 
depression or anxiety at an earlier stage, that might have recovered since then. 
4.1 Assessing proportions of symptoms 
There is some discrepancy in literature regarding the proportions of breast cancer survivors 
with symptoms of depression and anxiety10. Some studies report comparable results, were 
others report different figures 12, 23, 24. The prevalence of women with symptoms of depression 
and anxiety found in this study is low in comparison to other studies25, 26. The main explanations 
for these differences are the differences in follow-up time, differences in age of the included 
women, and the differences in applied questionnaires. The controls from our study had a lower 
proportion of women with severe symptoms of depression or anxiety compared to a European 
female population27. However, these proportions were within the confidence intervals of our 
control population: 2.9% severe symptoms of depression and 10.0% severe symptoms of 
anxiety, respectively. The European population was selected at random and might have included 
women with (a history of) cancer. In addition, the difference might be due to the younger age of 
the participants in the European population, which is associated with an increased score on the 
HADS questionnaire for symptoms of depression and anxiety28-30.  
4.2 Comparison symptoms with controls 
We found an increased odds of severe symptoms of depression and anxiety among long-term 
breast cancer survivors compared to controls. The mean scores in this study did not significantly 
differ. Claus et al. found significant higher mean scores for severe symptoms of depression 
among breast cancer survivors than among controls, measured with the CES-D questionnaire 
(mean follow-up 5.8 years)31. Klein et al. compared mean scores for severe symptoms of anxiety 
among long-term breast cancer survivors and controls and found significantly higher mean 
scores for survivors, measured with the STAI questionnaire (5, 10 or 15 years after breast 
cancer diagnosis)13.  
We found an increased odds of mild symptoms of depression among long-term breast cancer 
survivors compared to controls. None of the studies compared mild symptoms of depression or 
anxiety among breast cancer survivors and controls. Hoffman et al. evaluated psychological 
distress in a long-term cancer survivors cohort (22.9% breast cancer, ≥5 years after diagnosis) 
and found significantly more psychological distress among cancer survivors than among 
controls without cancer, measured with the self-reporting K6 scale, designed to assess 
nonspecific psychological distress32.  
4.3 History of depression 
A previous diagnosis of depression or prescription of antidepressants before the cancer 
diagnosis had no effect on the odds of having (severe) symptoms of depression or severe 
symptoms of anxiety for breast cancer survivors in comparison to controls in our population. In 
contrast, other research defined a history of depression as a risk factor for depression after 
breast cancer, but in that study the outcome measure was a diagnosis of depression and not 
symptoms of depression11. Interestingly, in our study all women (survivors and controls) with a 
history of depression had significantly more mild symptoms of anxiety. One could hypothesize 
that women with a history of depression are more anxious than others, perhaps by nature or 
they might fear recurrence of psychological distress. However, this was not the aim of this study 
and not evaluated further.  
4.4 Time since diagnosis 
Time since diagnosis was not associated with having (severe) symptoms of depression and 
severe symptoms of anxiety for breast cancer survivors. These results are in-line with the results 
of another study among survivors two to ten years after diagnosis33. Additionally, in a large long-
term cancer survivors cohort more than five years after cancer diagnosis, no association was 
found with time since diagnosis32. A significant difference of symptoms of depression one year 
after diagnosis compared to women in the general population appeared to decline in the 
following years10. A complete decline was not supported by the results of our study, as the time 
since diagnosis had no significant effect on the elevated odds of breast cancer survivors having 
symptoms of depression. 
4.5 Strengths and limitations 
The main strength of this study is that we have included a random sample of women from the 
general population. Although no other study included this unselected population, it can be 
argued that our population still does not include the mean breast cancer patient. Which is true, 
because the included patients were slightly younger and a higher percentage received 
radiotherapy. Therefore, we might underestimate the occurrence of anxiety and depression. 
Also, breast cancer survivors are more likely to be underdiagnosed than controls, because signs 
of depression or anxiety might be interpreted as “natural” consequences of cancer7. The median 
follow-up of 10 years is a strength, because it focusses exclusively on the long-term effects. In 
order to achieve a uniform outcome, we let all the participants complete the HADS 
questionnaire, hereby relying on the symptoms the women are experiencing at that point in 
time, rather than on patients’ help-seeking or doctors’ coding behaviour. It is important to 
realize that the HADS questionnaire only measures symptoms of depression; for an actual 
diagnosis of depression a clinical interview has to be performed. However, the HADS-D and 
HADS-A have a sensitivity and specificity of approximately 0.80 for depression and anxiety34. 
Furthermore, we adjusted for a history of depression before breast cancer as registered by GPs 
to ensure that an already psychologically delicate group did not influence the results. In both 
groups, women with depression or depressive symptoms might be less inclined to participate, 
making the comparison equal. Missing from our data is the diagnosis of anxiety disorder; 
unfortunately, this data was not retrieved from the GP databases. Notable, controls had more 
prescriptions of hypnotics/sedatives at the time of breast cancer diagnosis than the breast 
cancer survivors. However, the effect on the results is expected to be minimal since the number 
was comparable at the time of cross-sectional assessment. It should be taken into account that 
socioeconomic (SES), occupational and marital status were not assessed in this study.  
4.6 Conclusion 
At least five years after breast cancer, breast cancer survivors have a higher prevalence of 
(severe) symptoms of depression and severe symptoms of anxiety, even after adjusting for a 
history of depression prior to breast cancer. Future studies should take into account factors such 
as fatigue and SES.  However, in our study more than 80% of long-term breast cancer survivors 
did not have mild or severe symptoms of depression or anxiety.   
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Figure 1. Percentage of breast cancer survivors and controls with symptoms of 
depression, per two years after breast cancer diagnosis.* 
* Since the minimum of women per time-subgroup was 20, the subgroup goes up to 13-14 years 
after breast cancer diagnosis. 
 
 
Figure 2. Percentage of breast cancer survivors and controls with symptoms of anxiety, 
per two years after breast cancer diagnosis.* 
* Since the minimum of women per time-subgroup was 20, the subgroup goes up to 13-14 years 
after breast cancer diagnosis. 
TABLES 
Table 1: At the time of breast cancer diagnosis or index datea: Characteristics of breast 
cancer survivors and matched controls.  
 Breast cancer survivors 
(N = 350)b 
Controls 
 (N = 350)b 
Age at breast cancer diagnosis or index date for 
matched control; years, median (IQR) 
51 (45-57) 51 (45-57) 
   
 N (%) N (%) 
Breast cancer treatment as registered in the hospital 
and general practitioners files 
  
Chemotherapy 175 (50.0)  
Anthracycline-based 142 (81.1) – 





Trastuzumab 13 (3.7) – 
Anti-hormonal treatment 146 (41.7) – 
Radiotherapy 295 (84.3) – 
Diagnosis of depression or prescriptions before  the 
time of breast cancer diagnosis or index date for 
matched controla 
  
History of breast cancer: diagnosis of depression or 
antidepressantsd 
36 (10.3) 36 (10.3) 
A diagnosis of depressiond 14 (4.0) 21 (6.0) 
A prescription of any antidepressantsd 29 (8.3) 24 (6.9) 
A prescription of anxiolyticsd 39 (11.1) 37 (10.6) 
A prescription of hypnotics or sedativesd 13 (3.7) 33 (9.4) 
a The date of breast cancer diagnosis from the survivor was made identical for the matched control (index date); 
b There were no statistically significant differences between groups, tested with Chi-square test or Mann-Whitney U 
test, except for a prescription of hypnotics or sedatives; numbers in bold means significant at p <0.05 level;   
c Doxorubicin isotoxic dose, information available for 108 survivors (76%); 





Table 2: At time of cross-sectional measurement: Univariate comparison of outcomes 




(N = 350) 
Controls breast 
cancer survivors 
(N = 350) 
 
 
Follow-up durationa; years, median (IQR)  10 (7–14) 10 (7–14)  
Age: years, median (IQR) 63 (57-68) 63 (57-68)  
 N (%, 95%CI) N (%, 95%CI) OR (95%CI)b 
Depression     
HADS-Depressionc    
HADS-D ≥ 8 
HADS-D ≥ 11 
Continuous median (IQR)d 
37 (10.6, 7.3-13.9) 
13 (3.7, 1.7-5.7) 
2 (1-4) 
17 (4.9, 2.6-7.2) 





Anxiety     
HADS-Anxietyc 
HADS-A ≥ 8 
HADS-A ≥ 11 
Continuous median (IQR)d 
 
65 (18.6, 14.4-22.7) 
28 (8.0, 5.1-10.9) 
5 (3-7) 
 
57 (16.3, 12.3-20.2) 






Diagnosis of depression or prescriptions after 
time of breast cancer diagnosis or index date for 
matched controla 
   
First diagnosis of depressione 18 (5.1, 2.8-7.5) 13 (3.7, 1.7-5.7) 1.4 (0.7-2.9) 
First prescription of any antidepressante 41 (11.7, 8.3-15.2) 39 (11.1, 7.8-14.5) 1.1 (0.7-1.7) 
First prescription of any anxiolyticse 46 (13.1, 9.5-16.8) 49 (14.0, 10.3-17.7) 0.9 (0.6-1.4) 
First prescription of any hypnotics or sedativee 41 (11.7, 8.3-15.2) 34 (9.7, 6.5-12.9) 1.2 (0.8-2.0) 
a The date of breast cancer diagnosis from the survivor was made identical for the matched control (index date); 
b Numbers in bold means significant at p <0.05 level; 
c Explanation: HADS ≥ 8 = Symptoms of mild depression (HADS-D) or anxiety (HADS-A) and HADS ≥ 11 = symptoms of 
severe depression (HADS-D) or anxiety (HADS-A); 
d Tested with Mann-Whitney U test;  
e Extracted from electronic patient files of general practitioners. 
Table 3: Regression analyses: Comparison of outcomes at the time of cross-sectional 
measurement from the Hospital Anxiety Depression Scale (HADS) - Depression and 
Anxiety, between breast cancer survivors and matched controls. 
 HADS-D ≥ 8a HADS-D ≥ 11a HADS-A ≥ 8a HADS-A ≥ 11a 
  OR (95%CI)b OR (95%CI)b OR (95%CI)b OR (95%CI)b 
Univariate regression analyses     




















Multivariable regression analyses 
(adjusted for each other) 
    





















aExplanation: HADS-D (Depression) ≥ 8 = mild symptoms of depression and HADS-D ≥ 11 = severe symptoms of 
depression, HADS-A (Anxiety) ≥ 8 = mild symptoms of anxiety and HADS-A ≥ 11 = severe symptoms of anxiety; 
bNumbers in bold means significant at p <0.05 level; 
cThe determinant ‘history of depression’ was defined as a diagnosis of depression and/or prescription of an 




Supplementary figure 1. Design of the study.  
